Domestic pharmaceutical firms urged to augment actual R&D investment

Although some leading pharmaceutical firms have embarked for their sizable investments in R&D new drug projects, the majority of domestic pharmaceutical firms have concentrated their R&D outlays on labor costs, thus causing suspicions on the tangible outcome in the pharmaceutical community.

As shown in the following table, the combined R&D spending of local pharmaceutical firms in th...